ACUMEN PHARMACEUTICALS INC (ABOS) — insider trading
Health Care · NASDAQ
ACUMEN PHARMACEUTICALS INC (ABOS) has 28 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 28 (latest 2026-06-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Porter Derrell | Director | Option exercise / conversion (derivative) | 13,040 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Porter Derrell | Director | Open-market sale | 13,040 | $2.33 | $30.3K | Form 4 |
| 2026-06-17 | Porter Derrell | Director | Option exercise / conversion | 13,040 | $1.07 | $14.0K | Form 4 |
| 2026-06-16 | Porter Derrell | Director | Open-market sale | 12,800 | $2.33 | $29.8K | Form 4 |
| 2026-06-15 | Porter Derrell | Director | Option exercise / conversion (derivative) | 6,460 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Porter Derrell | Director | Open-market sale | 6,460 | $2.35 | $15.1K | Form 4 |
| 2026-06-15 | Porter Derrell | Director | Option exercise / conversion | 6,460 | $1.07 | $6.9K | Form 4 |
| 2026-06-09 | Fountain Nathan B | Director | Open-market sale | 6,400 | $2.23 | $14.3K | Form 4 |
| 2026-06-03 | Stoppel Laura | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Stoppel Laura | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Golumbeski George | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Golumbeski George | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Ives Jeffrey L. | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Ives Jeffrey L. | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Porter Derrell | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Porter Derrell | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Stalfort John A III | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Stalfort John A III | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Drapkin Kimberlee C | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Drapkin Kimberlee C | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Fountain Nathan B | Director | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Fountain Nathan B | Director | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-06-03 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 53,250 | $0.00 | $0 | Form 4 |
| 2026-06-03 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting | 35,500 | $0.00 | $0 | Form 4 |
| 2026-03-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting | 6,060,606 | $3.30 | $20.00M | Form 4 |
| 2026-03-06 | Meisner Derek M | Officer (Chief Legal Officer & Corp Sec) | Option exercise / conversion (derivative) | 2,090 | $0.00 | $0 | Form 4 |
| 2026-03-06 | Meisner Derek M | Officer (Chief Legal Officer & Corp Sec) | Open-market sale | 2,090 | $3.26 | $6.8K | Form 4 |
| 2026-03-06 | Meisner Derek M | Officer (Chief Legal Officer & Corp Sec) | Option exercise / conversion | 2,090 | $1.85 | $3.9K | Form 4 |
Ask the chat about ABOS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ACUMEN PHARMACEUTICALS INC (ABOS).
Last updated 2026-06-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.